Karyopharm Therapeutics

Karyopharm Therapeutics is a biopharmaceutical company with a focus on the development of novel drugs for the treatment of cancer, inflammation, and diseases related to cell proliferation. Karyopharm Therapeutics is developing small molecule drugs that will modulate the activity of critical pathways in cancer, inflammation, and cell proliferation (e.g. FOXO, NFкB, P53, pRB) by targeting the nuclear pore complex machinery, which controls the import and export of proteins between the nucleus and cytoplasm. To successfully control transport through the nuclear pore complex, the company will use its unique technology platform, developed by Sharon Shacham, to identify novel small molecules, optimize them into clinical candidates, and evaluate them in subsequent human clinical studies.

Karyopharm Therapeutics headquartered in United States, North America, operates in the Health Care, Pharmaceutical, Medical sector. The company focuses on Health Care and has secured $52.5B in funding across 96 round(s). With a team of 251-500 employees, Karyopharm Therapeutics is actively contributing to advancements in Health Care. Their latest funding round, Series A - Karyopharm Therapeutics, raised $20.0M. Discover more about their projects, partnerships, and impact on our platform.